Ju Fu Tang Biotech Releases FY25/26 Annual Report and AGM Materials, Opens Channels for Printed Copies

Bulletin Express
Jul 31

Ju Fu Tang Biotech Holdings Co., Ltd. announced on 31 July 2026 that its Annual Report for the financial year 2025/2026, together with the Notice of Annual General Meeting, the related circular and proxy form, are now available online.

The full English and Chinese versions can be accessed through: • Company website: www.todayir.com/en/showcases.php?code=8217 • Hong Kong Stock Exchange website: www.hkexnews.hk

Shareholders who hold their shares through CCASS and have not provided an email address to their intermediaries can request hard copies of the current and future corporate communications free of charge. To do so, they must complete the enclosed request form and return it to the Hong Kong branch share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, using the prepaid mailing label or by email at 8217-ecom@vistra.com.

Non-registered holders preferring electronic delivery should submit a functional email address to their bank, broker, custodian, nominee or HKSCC Nominees Limited to ensure timely receipt of publication notices. Until an email address is provided, these investors will receive printed notifications only.

Enquiries can be directed to Tricor’s hotline at (852) 2980 1333, Monday to Friday, 9:00 a.m.–6:00 p.m. (excluding public holidays).

The notification is issued by Executive Director Chen Jian on behalf of the board of Ju Fu Tang Biotech Holdings Co., Ltd.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10